ID   FHS025i-sh1649A
AC   CVCL_YY56
SY   iPSC - 1649A
DR   BioSample; SAMN06093674
DR   GEO; GSM2411769
DR   WiCell; fhs025i-sh1649a
DR   Wikidata; Q98126087
RX   PubMed=28388431;
CC   Part of: Framingham Heart Study (FHS) collection.
CC   Part of: Next Generation Genetic Association studies (Next Gen) program cell lines.
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G; dbSNP=rs12740374; Zygosity=Homozygous; Note=Major haplotype (PubMed=28388431).
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_YY57 ! FHS026i-sh1649B
SX   Female
AG   61-70Y
CA   Induced pluripotent stem cell
DT   Created: 02-07-20; Last updated: 29-06-23; Version: 7
//
RX   PubMed=28388431; DOI=10.1016/j.stem.2017.01.010;
RA   Warren C.R., O'Sullivan J.F., Friesen M., Becker C.E., Zhang X.-L.,
RA   Liu P.-C., Wakabayashi Y., Morningstar J.E., Shi X., Choi J., Xia F.,
RA   Peters D.T., Florido M.H.C., Tsankov A.M., Duberow E.A., Comisar L.,
RA   Shay J., Jiang X., Meissner A., Musunuru K., Kathiresan S.,
RA   Daheron L., Zhu J., Gerszten R.E., Deo R.C., Vasan R.S.,
RA   O'Donnell C.J., Cowan C.A.;
RT   "Induced pluripotent stem cell differentiation enables functional
RT   validation of GWAS variants in metabolic disease.";
RL   Cell Stem Cell 20:547-557.e7(2017).
//